8-K: Bio-Path Holdings Secures $161,000 Promissory Note from Quick Capital, LLC

Bio-Path Holdings enters into a securities purchase agreement with Quick Capital, LLC for a $161,000 promissory note with a 12% interest charge and potential conversion rights upon default.

Summary

• Bio-Path Holdings, Inc. has entered into a securities purchase agreement with Quick Capital, LLC for a promissory note with a principal amount of $161,000.
• The purchase price for the note is $140,000, reflecting an original issue discount of $21,000.
• The note carries a one-time interest charge of 12% applied on the issuance date, April 28, 2025.
• The note is to be repaid in five payments starting October 15, 2025, with an initial payment of $90,160 followed by four payments of $22,540 each.
• The maturity date for the note is February 15, 2026.
• Upon an Event of Default, the note becomes immediately due and payable, with the amount due being 150% of the outstanding principal plus accrued interest and any default interest at a rate of 22% per annum.
• Quick Capital, LLC has the option to convert the outstanding principal and interest into shares of Bio-Path Holdings' common stock upon an Event of Default, with the conversion price set at 65% of the lowest closing bid price for the ten trading days prior to conversion.
• The lender is restricted from converting the note to the extent that they would own more than 4.99% of the company's outstanding common stock after conversion.
• The issuance of the note and any shares issued upon conversion will not be registered under the Securities Act of 1933.
• Bio-Path Holdings is required to maintain a listing of its common stock on at least one of the specified exchanges or quotation platforms.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the financing provides immediate capital, the high cost and restrictive terms raise concerns about the company's financial health and future prospects.

Positives

• Bio-Path Holdings secures immediate funding of $140,000.
• The company has the right to prepay the note in full at any time with no prepayment penalty.
• The agreement includes a five-day grace period for each payment.
• The company retains control over its operations, with the lender's consent required only for significant asset sales outside the ordinary course of business.

Negatives

• The effective interest rate on the note is high due to the original issue discount and the 12% interest charge.
• An Event of Default triggers a significant penalty of 150% of the outstanding amount plus a 22% default interest rate.
• The lender has the right to convert the debt into equity upon default, potentially diluting existing shareholders.
• The company's ability to sell assets is restricted without the lender's consent.
• The company is responsible for covering the lender's legal and broker fees, totaling $16,500.

Risks

• Failure to make timely payments on the note constitutes an Event of Default, triggering significant financial penalties and potential conversion of debt to equity.
• Breach of any material covenant or representation could lead to an Event of Default.
• Delisting of the company's common stock from a specified exchange would trigger an Event of Default.
• The conversion of the note into common stock could dilute existing shareholders' equity.
• The company's ability to raise additional capital may be limited by the terms of the note.
• The company's operations are subject to cross-default provisions with other agreements with the lender.

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the terms of the promissory note and purchase agreement.

Industry Context

This type of financing is common for small-cap companies, particularly in the biotech sector, seeking to raise capital. The terms, including the high interest rate and default penalties, reflect the higher risk associated with investing in such companies.

Comparison to Industry Standards

• The interest rate of 12% and default interest rate of 22% are relatively high compared to traditional bank loans, reflecting the higher risk profile of Bio-Path Holdings.
• The conversion feature, allowing the lender to convert debt into equity upon default, is a common feature in financing agreements with small-cap companies.
• The 35% discount on the conversion price is within the typical range for such agreements, but the specific percentage depends on the company's financial condition and market outlook.
• Similar deals in the biotech industry often include warrants or other equity incentives for the lender, which are not present in this agreement.
• The cross-default provision, linking this loan to other agreements between Bio-Path Holdings and Quick Capital, LLC, is a standard risk mitigation measure for lenders.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may be affected by any operational changes resulting from the financing.
• Customers and suppliers may be impacted by the company's ability to continue operations and meet its obligations.
• Creditors may be affected by the company's increased debt burden and the cross-default provisions.

Next Steps

• Bio-Path Holdings will use the proceeds for general working capital purposes.
• The company will make five payments to Quick Capital, LLC, starting October 15, 2025.
• The company must comply with the reporting requirements of the Securities Exchange Act of 1934.
• The company must maintain its stock listing on a specified exchange.
• The company must issue irrevocable instructions to its transfer agent to facilitate the conversion of the note into common stock upon default.

Key Dates

Keywords

promissory note, securities purchase agreement, Quick Capital LLC, Bio-Path Holdings, Event of Default, conversion rights, common stock, financing, debt, investment